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increased mortality from tumor in recipients of 7
/
 donor T
cells, suggesting preservation of any graft-versus-tumor activity.
We are currently performing further studies to look at histopa-
thology of GVHD target organs and to analyze T cell inﬁltrates in
GVHD target organs. In summary, 7
/
 donor T cells as
compared to wild type donor T cells cause less GVHD morbidity
and mortality. Our data suggest that strategies that interfere with
the 7 integrin have clinical potential to alleviate or prevent
GVHD while preserving GVT activity.
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DETERMINANTS OF ANTILEUKEMIA EFFECTS OF ALLOGENEIC NATU-
RAL KILLER CELLS
Leung, W.1, Iyengar, R.1, Turner, V.1, Lang, P.2, Bader, P.2, Conn,
P.1, Niethammer, D.2, Handgretinger, R.1 1. St. Jude Children’s
Research Hospital, Memphis, TN; 2. Children’s University Hospital,
Tuebingen, Germany.
In HLA-nonidentical bone marrow transplantation, we sought to
determine the characteristics of donor NK cells, recipient leukemia
cells, and the cytokine environment that predict the antileukemia
effects of allogeneic NK cells. We found that the risk of leukemia
relapse in a prospective cohort of 36 pediatric patients was best
predicted by a model taking into consideration the presence of
inhibitory killer-cell immunoglobulin-like receptors (KIRs) on the
donor’s NK cells and the absence of corresponding KIR ligand in
the recipient’s HLA repertoire (a receptor-ligand model). The risk
of relapse was prognosticated less precisely by the Perugia donor-
recipient KIR ligand-ligand mismatch model or by a natural cyto-
toxicity model. In contrast to the Perugia model, we found that the
new receptor-ligand model was accurate when analysis was applied
to patients with lymphoid malignancy. These ﬁndings corroborate
our observations that the recipient’s KIR repertoire, which was
derived from highly puriﬁed HLA-disparate CD34 cells, always
resumed a donor-speciﬁc pattern within 3 months of transplanta-
tion but did not correlate evidently with either the donor or
recipient ligand repertoire. In an in vitro assay and an in vivo
mouse model, human NK-cell cytotoxicity toward human leuke-
mia cells with 11q23 chromosomal rearrangement increased with
the number of receptor-ligand mismatch pairs or prestimulation
with IL-12 and IL-18. These ﬁndings provide new insights into the
determinants of antileukemia effects of allogeneic NK cells and
therapeutic strategies.
121
PROTEINURIA RELATED TO CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Carrasco-Yala´n, A.A.1, Murillo-Vizcarra, S.A.1, Moreno-Larrea, M.1,
Chumpitaz-Anchiraico, G.1, Castillo-Aguirre, J.1, Mendoza, S.1, So-
mocurcio-Peralta, J.2, Liendo-Liendo, C.3, Navarro-Cabrera, J.R.1 1.
BMT Unit-Hematology Department; 2. Anatomy Pathology Depart-
ment; 3. Nephrology Department. Edgardo Rebagliati-Martins National
Hospital. ES-SALUD, Lima, Peru.
Proteinuria related to chronic graft-versus-host disease (GVHD)
is an uncommon manifestation post allogeneic stem cell transplan-
tation (SCT). Several papers have recently addressed this issue. We
report our experience in four allogeneic SCT. Between April-2001
to November-2002, four women received full matched sibling
allografts for aplastic anemia (n  2), RAEB-I (n  1) and CML
(n  1). Median age 28 years (range 20-40). Median time from
diagnosis to transplantation was 7 months (range 6-12). Condi-
tioning regimen for aplastic anemia was: antilymphocyte globu-
lin  cyclophosphamide , for RAEB-I: total body irradiation 
cyclophosphamide, ﬁnally for CML: Busulfan p.o. cyclophosph-
amide. GVHD prophylaxys were given with cyclosporine and
methrothexate . All patient engrafted, neutrophils engraftment at
median of 10 days (range 9-11), non-platelets failure was observed.
Acute GVHD was observed in three cases. Proteinuria during
chronic GVHD exacerbation was developed at a median time of 12
months (range 10-18) post peripheral blood SCT. None of them
developed renal failure neither hypertension. Edema and hy-
poalbuminemia was observed in several degrees. During chronic
GVHD exacerbation, one patient developed lung GVHD, another
polimyositis and two showed positivity to cytomegalovirus (CMV)
antigenemia with extensive GVHD manifestations. Two of them
developed proteinuria at nephrotic range. Renal biopsies were
carried out showing: diffuse proliferative glomerulonephritis,
membranous nephropathy with IgG , C3 and Lambda immune
complex deposit (F/24) and focal intersticial atrophy and ﬁbrosis,
mild membranous nephropathy with C1q immune complex deposit
(F/32). Prednisone based therapy with mycophenolate mofetil (n
3) and cyclosporine (n  1) combined with gancyclovir for CMV
antigenemia, resulted in renal function stabilization and gradual
proteinuria decreases. Currently all of the patients are still alive in
complete remission without transfusion and chronic GHVD im-
provement. Our data suggest that the kidney may be a target organ
in chronic GVHD with immune complex-mediated disease. Fi-
nally we recommend that proteinuria has to be tested under
chronic GVHD exacerbations.
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TACROLIMUS IN COMBINATION WITH STEROIDS FOR THE TREATMENT
OF CHRONIC GVHD
De Jesus, J., Ghosh, S., Hsu, Y., Neuman, J., Cohen, A., Champlin, R.,
Couriel, D. UT MD Anderson Cancer Center, Houston, TX.
Background: Tacrolimus is an effective drug for the treatment of
graft-versus-host disease (GvHD). Recent studies have shown that
tacrolimus may be better than cyclosporine for the prevention of
GvHD. Other studies have shown that it was an effective salvage
therapy for chronic GvHD, even in patients previously treated
with cyclosporine. We report the efﬁcacy of tacrolimus/steroids as
frontline treatment of chronic GvHD. Methods: Retrospective
evaluation of 104 patients who had an allogeneic HSCT between
1/99-12/00 treated with a combination of tacrolimus and steroids
for chronic GvHD. Results: Among the 104 patients (M/F 
74/30), 64 had HLA-matched sibling, 36 matched unrelated and 4
mismatched related transplants. The underlying diseases included:
AML/MDS  33, CML/MPD  25, Lymphoma  28, ALL/
CLL 11, Myeloma 4, others 3. Chronic GvHDwas de novo
in 33 cases, relapsing in 59 and progressive in 12 patients. The
disease was limited in 20 and extensive in 84 patients. In 79% cases
2 organs were involved (skin 84, liver 43, mouth 40, GI
37, eyes  24, lung  13, hematologic  13, musculoskeletal  2,
other  5). GvHD was documented by histology in 56/81 cases
where biopsy examination was performed at the time or following
diagnosis of chronic GvHD. The overall CR/PR rate to tacroli-
mus/steroids was 72% (n  75). Twenty-eight (27%) patients
developed did not respond (NR) or developed progressive disease
(PD). The majority of responses were seen in skin (n  56, 79%)
and oral (n  19, 76%) chronic GvHD. Most failures were seen in
patients with GVHD of the eye (n  5, 50%), GI tract (n  11,
41%) and liver (n  9, 29%). In 49 cases (47%) salvage immuno-
suppression was required after ﬁrst line treatment with tacrolimus/
steroids. The majority of patients (n  34, 69%) responded to
salvage therapy. Fifty patients (48%) in this series died with an
overall cGvHD-related mortality of 34%. Conclusions: Responses
Table. Patients Characteristics
Sex/age
Primary
Disease
Acute-
GVHD
Chronic-
GVHD
Initial
Proteinuria
(mg/24 h)
Proteinuria
Post-SCT
(months)
F/32 Aplastic anemia II Extensive 1248 18
F/40 Aplastic anemia I Extensive 466 15
F/24 RAEB I II Extensive 2294 10
F/20 CML Ph  1CP none Extensive 427 10
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to ﬁrst line therapy with tacrolimus/steroids is high. How-
ever, a substantial number of patients required salvage treat-
ment and mortality continues to be high. Earlier intervention
for the prevention of both acute and chronic forms of GvHD is
warranted.
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PENTOSTATIN AND CYCLOSPORINE, A NEW REGIMEN FOR THE
PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL TRANSPLAN-
TATION
Schwartz, J.E., Carroll, M.P., BuchBarker, D.M., Grifﬁn, D.L.,
Schwartz, R.N., Tompkins, C.A., Donnenberg, A.D., Agha, M.E.,
Evans, C., Burgunder, M.R., Yeager, A.M. University of Pittsburgh
Cancer Institute, Pittsburgh, PA.
Acute graft-versus-host disease (AGVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic cell
transplantation. Common preventive strategies include cyclo-
sporine (CSP) or tacrolimus plus short-course iv methotrexate
(MTX). Pentostatin (PEN), a purine nucleoside analog, has
been used to treat steroid-refractory acute and chronic GVHD
but not to prevent AGVHD. We conducted a phase II study to
evaluate the efﬁcacy of short-course PEN plus CSP for GVHD
prophylaxis in 10 patients (pts) (6 M, 4 F; median age 34 yr;
range 18-49 yr) with AML(1), ALL(2), CML(2), NHL(3)
MM(2) who were undergoing allogeneic PBPCT from HLA-
identical sibs. Preparative regimens were: busulfan (BU) and
cyclophosphamide(CY) (5); total body irradiation(TBI) and CY
(2); BU, CY and etoposide (2); or TBI and melphalan (1). All pts
received CSP, initially by continuous iv infusion, beginning at
day (d) –2. PEN was administered i.v. at a dose of 1.0 mg/m2 on
d1 and at a dose of 0.5 mg/m2 on d3, 6 and 11. Pts
received a median of 9.24 (range, 5.38–13.9) x 106 CD34
cells/kg and a median of 3.52 (range 2.03–6.02) x 108 CD3
cells/kg. Median time to absolute lymphocyte count (ALC) 0.2
x 109/L was 9d (range, 0-13 d) after PBPCT and to absolute
neutrophil count (ANC) 0.5 x 109/L was 10d (range, 8-15 d).
In 9 pts, the median time to attain platelets 20 x 109/L was 16d
(range, 10-27 d); 1 pt never had platelet recovery. Grades of
AGVHD were: 0 (2), I (1), II (3), III (3) and IV (1). The
incidence of Grade II-IV AGVHD was 70% and of Grade
III-IV AGVHD was 40%. AGVHD responded to steroids in 3
pts but was steroid-refractory in 4 pts, requiring mycophenolate
mofetil (MMF; 2 pts) or MMF plus anti-thymocyte globulin (2
pts). Two pts died from GVHD-related complications at d108
and d112 after PBPCT. All 8 evaluable pts developed chronic
GVHD (CGVHD; 2 limited, 6 extensive); extensive CGVHD
developed in 3 pts after intentional withdrawal of immunosup-
pression and in 1 pt because of non-compliance with CSP.
Three pts (1 AML, 1 ALL, 1 MM) relapsed at d180, 188 and
266, respectively; 2 attained remissions after immunosuppres-
sion withdrawal. Eight pts are alive at a median of 443 d
(range, 181–721 days) after PBPCT (overall survival, 80%).
We conclude that PEN may be an alternative to MTX for
AGVHD prophylaxis. The observed incidence of Grade II-IV
AGVHD and of CGVHD suggests that higher doses and/or
longer duration of PEN may be needed to improve efﬁcacy of
this regimen.
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COMPARISON OF LYMPHOID AND MYELOID ENGRAFTMENT RATES IN
PATIENTS RECEIVING FLUDARABINE/TBI OR FLUDARABINE/CYCLO-
PHOSPHAMIDE FOR NON-MYELOABLATIVE ALLOGENEIC TRANSPLAN-
TATION
Mellon-Reppen, S., Dansey, R., Abella, E., Nehlsen-Cannarella, S.,
Abidi, M.H. Karmanos Cancer Institute, Detroit, MI; Wayne State
University, Detroit, MI.
Non-myeloablative allogeneic transplants are used in place of
ablative transplants in selected patients with poor performance
status or abnormal vital organ function. They have been per-
formed in patients with low grade NHL, Hodgkin’s disease,
multiple myeloma and renal cell carcinoma. The conditioning
regimen is an important element of the procedure as it contrib-
utes to the speed and rate of donor lymphoid and myeloid
engraftment.
We report engraftment and GVHD rates of ﬂudarabine/TBI
(FluTBI) compared to ﬂudarabine/cyclophosphamide (FluCy).
From 09/2000 to the present, ﬂudarabine 30mg/m2 x 3 days
with TBI 200cGy was given to 12 patients and ﬂudarabine
25mg/m2 x 5 days with cyclophosphamide 60mg/m2 x 2 days was
given to 28 patients. Post-transplant immunosuppression was
identical for both regimens with mycophenolate and cyclo-
sporine. Diagnoses included renal cancer 13, myeloma 7, NHL
6, AML/MDS 4, breast cancer 3, Hodgkin’s disease 3, CLL 2,
CML 1 and pancreatic cancer 1. Twenty three donors were
siblings and 17 were unrelated volunteers. Lymphoid and
myeloid engraftment were evaluated by peripheral blood STR
and expressed as percent donor cells. Results are reported as
median values. By ANOVA testing there are signiﬁcant differ-
ences between conditioning regimens for lymphoid engraftment
at day 14 (p  0.027) and day 28 (p  0.024). The range of
percent donor lymphoid cells was similar for both regimens at
all time points. Two (17%) patients who received FluTBI re-
jected the graft. One patient was reconditioned successfully with
FluCy. No patients receiving FluCy rejected. Acute graft versus
host disease occurred in 66% of patients conditioned with
FluCy compared to 58% (p  NS) receiving FluTBI and
chronic graft versus host disease occurred in 45% of FluCy
patients versus 50% (p  NS) of FluTBI patients. Twelve (29%)
patients have achieved CR with no difference (28% FluCy vs
33% FluTBI) between conditioning regimens.
FluCy is associated with signiﬁcantly more rapid donor lymphoid
engraftment and this is potentially important when attempting to
balance regimen morbidity with need for engraftment due to
disease progression.
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ABSENCE OF INDUCIBLE COSTIMULATOR ON ALLOREACTIVE T CELLS
REDUCES GRAFT-VERSUS-HOST-DISEASE WHILE LEAVING GRAFT-VER-
SUS-TUMOR ACTIVITY INTACT
Tjoe, K.H., Eng, J.M., Alpdogan, O., Muriglan, S.J., Hubbard, V.M.,
Kochman, A.A., Schiro, R., van den Brink, M.R.M. Memorial Sloan-
Kettering Cancer Center, New York, NY.
Inducible costimulator (ICOS) has been recognized as a costimu-
latory molecule essential in T cell activation. Studies with ICOS
inhibition or ICOS
/
 recipients have demonstrated prolonged
allograft survival after heart or liver transplantation in animal
models. We hypothesized that inhibition of ICOS on alloreactive
Table. Engraftment Data Related to Conditioning Regime
Day Post-BMT 14 30 60 90 180 360
% Donor lymphoid FluCy 95 95 95 100 100 100
% Donor lymphoid FluTBI 63 78 87 75 100 100
% Donor myeloid FluCy 95 94 95 100 100 100
% Donor myeloid FluTBI 55 100 99 100 100 100
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